Adynxx (ADYX) 10-Q 10 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 10, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1,054,274
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		5,005,210

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 11,021	$ 2,181
Accounts receivable, net	442	99
Inventory, net	139	93
Prepaid expenses and other current assets	180	41
Current assets of discontinued operations	1,224	5,062
Total current assets	13,006	7,476
Improvements and equipment, net	367	522
Other assets	178	173
Assets of discontinued operations - noncurrent	0	24,769
Total assets	13,551	32,940
Current Liabilities:
Accounts payable	509	684
Accrued expenses and other current liabilities	249	712
Warrant liability	164	130
Current liabilities of discontinued operations	2,300	15,443
Total current liabilities	3,222	16,969
Other long-term liabilities	55	59
Long term liabilities of discontinued operations	0	245
Total liabilities	3,277	17,273
Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 95,000,000 shares authorized; 5,005,210 and 4,986,034 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	5	5
Additional paid-in capital	166,651	165,672
Accumulated deficit	(156,382)	(150,010)
Total stockholders’ equity	10,274	15,667
Total liabilities and stockholders’ equity	$ 13,551	$ 32,940

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	5,005,210	4,986,034
Common stock, shares outstanding	5,005,210	4,986,034

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue, net of returns, allowances and discounts	$ 864	$ 616	$ 1,408	$ 855
Cost of revenues	593	513	1,010	935
Gross profit/(loss)	271	103	398	(80)
Operating expenses
Selling, general and administrative	1,275	1,407	3,146	2,536
Business development costs	201	0	201	635
Total operating expenses	1,476	1,407	3,347	3,171
Loss from operations	(1,205)	(1,304)	(2,949)	(3,251)
Other (expense) income
Interest income	4	2	5	4
Change in fair value of warrant liability	(15)	250	(34)	369
Loss on early extinguishment of debt, net	(1,706)	0	(1,706)	0
Total other (expense) income	(1,717)	252	(1,735)	373
Loss from continuing operations before tax	(2,922)	(1,052)	(4,684)	(2,878)
Income tax benefit (expense)	3	(3)	0	(6)
Loss from continuing operations	(2,919)	(1,055)	(4,684)	(2,884)
Discontinued operations:
Loss from discontinued operations, net of tax of $0, for the three and six months ended June 30, 2018 and 2017	(3,864)	(3,149)	(7,207)	(8,317)
Gain on sale of assets, net of tax of $0.5 million for the three and six months ended June 30, 2018	5,521	0	5,521	0
Income/(loss) from discontinued operations, net of tax	1,657	(3,149)	(1,686)	(8,317)
Net loss	$ (1,262)	$ (4,204)	$ (6,370)	$ (11,201)
Net loss per basic and diluted common share:
Loss from continuing operations	$ (0.66)	$ (0.23)	$ (1.07)	$ (0.76)
Loss from discontinued operations	(0.88)	(0.70)	(1.65)	(2.19)
Gain on sale of assets	1.25	0	1.27	0
Total from discontinued operations	0.37	(0.70)	(0.38)	(2.19)
Net loss per basic and diluted common share	$ (0.29)	$ (0.93)	$ (1.45)	$ (2.95)
Weighted average shares used in computing net loss per basic and diluted common share	4,407,168	4,523,689	4,358,866	3,801,527

CONSOLIDATED STATEMENTS OF OPE5

CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period	$ 0	$ 0	$ 0	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	$ 500		$ 500

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating Activities
Net loss	$ (6,370)	$ (11,201)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,714	2,761
Amortization of deferred lease incentive	(16)	(23)
Deferred income tax expense	0	6
Provision for doubtful accounts	497	75
Reserve for note receivable	0	350
Provision for excess and slow moving inventory	(8)	12
Stock-based compensation expense	980	918
Deferred rent	2	3
Amortization of debt issuance and discount costs	254	425
Loss on early extinguishment of debt	1,706	0
Warrant modification expense	0	803
Change in fair value of warrant liability	34	(369)
Fair value adjustment of contingent consideration liability	0	35
Gain on sale of assets	(5,521)	0
Changes in operating assets and liabilities:
Accounts receivable	1,297	(887)
Inventory	(159)	(93)
Prepaid expenses and other assets	15	494
Accounts payable	525	56
Accrued expenses and other liabilities	(2,408)	(1,349)
Net Cash Used in Operating Activities	(7,458)	(7,984)
Investing Activities
Proceeds from sale of assets	29,000	0
Purchase of improvements and equipment	89	(79)
Issuance of bridge loan	0	(350)
Release of escrow deposit	100	0
Net Cash Provided by (Used In) Investing Activities	29,189	(429)
Financing Activities
Contingent purchase price payments	0	(675)
Net proceeds from bridge loan	1,712	0
Repayment of long-term debt	(14,135)	0
Fees paid on early extinguishment of debt	(466)	0
Net proceeds from issuance of common stock	0	5,865
Payment of withholding taxes related to stock-based employee compensation	(2)	(58)
Net Cash Provided by (Used In) Financing Activities	(12,891)	5,132
Net Increease (Decrease) in Cash and Cash Equivalents	8,840	(3,281)
Cash and Cash Equivalents - Beginning of period	2,181	5,580
Cash and Cash Equivalents - End of period	11,021	2,299
Supplemental Disclosure of Cash Flows Information
Interest	362	620
Non-cash investing and financing activities:
2016 Accrued bonus awarded in equity	0	374
2015 Accrued bonus awarded in equity	0	0
Common stock issued for contingent purchase price payments	$ 0	$ 1,175

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	Description of Business and Basis of Presentation Alliqua BioMedical, Inc. (the “Company”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company believes that it is one of the leading manufacturers of high performance gels in the United States. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company has, historically, served as a contract manufacturer, supplying its gels to third parties who incorporate them into their own products. On May 7, 2018, the Company completed its previously announced Asset Sale Transaction (the “AST”) with Celularity, Inc. (“Celularity”), pursuant to which the Company sold substantially all of its assets to Celularity, including certain assets comprising its MIST, Biovance and Interfyl Product Lines (the “Purchased Assets”). As consideration for the Purchased Assets, Celularity paid $ 29.0 14.8 The transactions contemplated by the APA were approved by the affirmative vote of a majority of the voting power of issued and outstanding shares of the Company’s common stock on April 27, 2018. The Company’s operations sold under the APA have been reclassified to discontinued operations in the second quarter of 2018, when the shareholders of the Company approved the sale. The AST was completed on May 7, 2018. The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of June 30, 2018 and results of operations and cash flows for the three and six months ended June 30, 2018 and 2017. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Annual Report”). The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year. The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation. Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported. In addition to the aforementioned AST with Celularity, effective August 31, 2017 the Company entered into an Asset Purchase Agreement (“the Argentum Purchase Agreement”) with Argentum Medical, LLC. (“Argentum”) whereby the Company agreed to sell to Argentum all of the Company’s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Argentum Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $ 3.6 0.1 3.6 0.3 0.1 0.2 Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Revenue, net of returns, allowances and discounts $ 1,844 $ 4,905 $ 6,681 $ 9,261 Cost of revenues 504 1,337 1,791 2,575 Gross profit 1,340 3,568 4,890 6,686 Selling, general and administrative 5,140 6,088 11,485 13,031 Interest expense 64 596 612 1,169 Warrant modification expense - 33 - 803 Loss from discontinued operations, net of tax (3,864) (3,149) (7,207) (8,317) Note: The discontinued operations were sold on May 7, 2018. Non-cash amortization expense of $ 0.4 1.2 1.4 2.3 5.5 0.5 Proceeds from sale Total Consideration 29,000 Less: Net book value of assets sold to Celularity Inventory, net (1,578) Intangibles, net (20,557) Goodwill (1,659) Fixed Assets, net (904) Other current assets 15 Total net book value of assets (24,683) Add: Net book value of liabilities extinguished due to sale Milestone payment 1,000 Other liabilities 717 Total net book value of liabilities 1,717 Less: State tax expense (513) Net gain on sale of assets $ 5,521 June 30, December 31, 2018 2017 Accounts receivable, net $ 1,024 $ 3,161 Inventory, net - 1,458 Prepaid expenses and other current assets 200 443 Total current assets 1,224 5,062 Fixed assets, net - 1,041 Intangible assets, net - 22,069 Goodwill, net - 1,659 Total assets of discontinued operations 1,224 29,831 Accounts payable 2,169 957 Accrued expenses and other current liabilities 131 3,557 Senior secured term loan, net - 10,929 Total current liabilities $ 2,300 $ 15,443 Other long-term liabilities - 245 Total liabilities of discontinued operations $ 2,300 $ 15,688 The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies In June 2018, the FASB issued ASU 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”. The amendments in this update is to maintain or improve the usefulness of the information provided to the users of financial statements while reducing cost and complexity in financial reporting. The areas for simplification in this Update involve several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, to include share-based payment transactions for acquiring goods and services from nonemployees. Some of the areas for simplification apply only to nonpublic entities. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements. In February 2018, the FASB issued ASU 2018-02, “Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in this Update also require certain disclosures about stranded tax effects. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Going Concern The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has experienced recurring losses since its inception. For the six months ended June 30, 2018, the Company incurred a net loss of $ 6.4 7.5 156.4 These factors raised substantial doubt as to the Company’s ability to continue as a going concern. Upon closing the APA, the Company received gross proceeds of $ 29.0 14.8 11.0 Given the Company’s current cash position and reduced cash burn, the Company believes substantial doubt has been mitigated and it has sufficient resources to support its planned operations for a year from the date these financial statements are issued.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	3. Revenue Recognition On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing accounting principles generally accepted in the United States of America (“U.S. GAAP”) including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption. The adoption of ASC 606 did not have a material impact on the Company’s condensed consolidated financial statements as of the date of adoption. As a result, a cumulative-effect adjustment was not required. The Company recognizes revenue predominately from one type of revenue, contract manufacturing and recognizes an immaterial amount from the sale of products. Revenue from both contract manufacturing and products is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. To achieve this core principle, the Company applies the following five steps: Step 1 – Identify the Contract with the Customer – A contract exists when (a) the parties to the contract have approved the contract and are committed to perform their respective obligations, (b) the entity can identify each party’s rights regarding the goods or services to be transferred, (c) the entity can identify the payment terms for the goods or services to be transferred, (d) the contract has commercial substance and it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Step 2 – Identify Performance Obligations in the Contract – Upon execution of a contract, the Company identifies as performance obligations each promise to transfer to the customer either (a) goods or services that are distinct or (b) a series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. To the extent a contract includes multiple promised goods or services, the Company must apply judgement to determine whether the goods or services are capable of being distinct within the context of the contract. If these criteria are not met, the goods or services are accounted for as a combined performance obligation. Step 3 – Determine the Transaction Price – The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring products or services to the customer. Generally, all contracts include fixed consideration. If a contract did include variable consideration, the Company would determine the amount of variable consideration that should be included in the transaction price based on expected value method. Variable consideration would be included in the transaction price, if in the Company’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract would not occur. Step 4 – Allocate the Transaction Price – After the transaction price has been determined, the next step is to allocate the transaction price to each performance obligation in the contract. If the contract only has one performance obligation, the entire transaction price will be applied to that obligation. If the contract has multiple performance obligations, the transaction price is allocated to the performance obligations based on the relative standalone selling price (SSP) at contract inception. Step 5 – Satisfaction of the Performance Obligations (and Recognize Revenue) – When an asset is transferred, and the customer obtains control of the asset (or the services are rendered), the Company recognizes revenue. At contract inception, the Company determines if each performance obligation is satisfied at a point in time or over time. Revenue from both product sales and contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. Disaggregation of Revenue The Company recognizes revenue predominately from contract manufacturing and recognizes an immaterial amount from products. Revenue from both products and contract manufacturing is recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time it ships the product to the customer. As of June 30, 2018, or December 31, 2017, the Company did not have any contract assets or contract liabilities from contracts with customers. During the three and six months ended June 30, 2018 and 2017, there was no revenue recognized from performance obligations satisfied (or partially satisfied) in previous periods. As of June 30, 2018, there were no remaining performance obligations that the Company had not satisfied.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	4. Net Loss Per Common Share Basic loss per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted loss per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock. As of June 30, 2018 2017 Stock options 706,666 921,050 Warrants 400,307 517,167 Non-vested restricted stock 20,000 261,603 Total 1,126,973 1,699,820

Inventory

Inventory	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5. Inventory June 30, December 31, 2018 2017 Raw materials $ 129 $ 98 Work in process 8 - Finished goods 2 - Less: Inventory reserve for excess and slow moving inventory - (5) Total $ 139 $ 93

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2018
Payables and Accruals [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	Accrued Expenses and Other Current Liabilities June 30, December 31, 2018 2017 Salaries, benefits and incentive compensation $ 71 $ 509 Professional fees 129 176 Other 49 27 Total accrued expenses and other current liabilities $ 249 $ 712

Debt

Debt	6 Months Ended
	Jun. 30, 2018
Debt Instruments [Abstract]
Long-term Debt [Text Block]	Debt Senior Secured Term Loan Facility On May 29, 2015, the Company entered into the CAG with Perceptive Credit Opportunities Fund, L.P. The CAG provided a senior secured term loan in a single borrowing to the Company in the principal amount of $ 15.5 On March 13, 2018, the Company, AquaMed Technologies, Inc., a wholly owned subsidiary of the Company, and Perceptive entered into an Amendment Agreement, pursuant to which the parties agreed to certain amendments and modifications to the terms of the CAG. The Amendment Agreement provided for, an additional bridge term loan to the Company in the aggregate principal amount of $ 2.0 0.25 The BLN bore interest at a rate per annum equal to the sum of (i) the greater of (x) LIBOR and (y) 1%, plus (ii) an applicable margin of 9.75%. On May 7, 2018, the Company paid approximately $ 14.8

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies License Agreement with Noble Fiber Technologies, LLC On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75 Litigation, Claims and Assessments From time to time, the Company may become involved in lawsuits, investigations and claims that arise in the ordinary course of business. The Company believes it has meritorious defenses against all pending claims and intends to vigorously pursue them. While it is not possible to predict or determine the outcomes of any pending actions, the Company believes the amount of liability, if any, with respect to such actions, would not materially affect its financial position, results of operations or cash flows. On February 22, 2018, a putative stockholder class action complaint was filed in the United States District Court for the District of Delaware against the Company and each member of the Board, captioned Ronald Cresta, Individually and on Behalf of All Others Similarly Situated v. Alliqua BioMedical Inc., David Johnson, Joseph M. Leone, Gary Restani, Jeffrey Sklar and Mark Wagner. The complaint alleges, among other things, that the Company and the Board violated federal securities laws and regulations by soliciting stockholder votes in connection with the AST through a proxy statement that omits material facts necessary to make the statements therein not false or misleading. The complaint seeks, among other things, to enjoin the Company and the Board from conducting the stockholder vote on the AST unless and until the allegedly omitted material information is disclosed to the Company’s stockholders, damages allegedly suffered by the plaintiffs as a result of the asserted omissions, as well as related attorneys’ fees and expenses. On April 4, 2018, the court approved the parties’ stipulation and proposed order to withdraw the motion for preliminary injunction and dismiss the action and the case was closed. The court retained jurisdiction of the action solely for determining any potential fee application if the parties are unable to reach agreement and a fee application becomes necessary.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2018
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Stockholders’ Equity Stock-Based Compensation On May 7, 2018, in connection with the closing of the sale under the APA of substantially all of the Company’s assets to Cellularity, which triggered certain change in control provisions of the Company’s equity plans, all unvested and outstanding options and restricted stock awards under the 2011 Plan and 2014 Plan became vested and exercisable. Options Outstanding Options Exercisable Range of Weighted Outstanding Weighted Average Weighted Exercisable $2.00 - $4.00 $ 3.51 215 3.51 2.3 215 $4.10 - $9.90 8.53 28 8.53 6.3 28 $10.00 - $19.90 10.57 76 10.57 1.2 76 $20.00 - $29.90 23.80 1 23.80 0.1 1 $30.00 - $39.90 33.63 46 33.63 4.3 46 $40.00 - $49.90 46.34 69 46.34 1.7 69 $50.00 - $59.90 52.92 43 52.92 1.1 43 $60.00 - $69.90 66.09 176 66.09 3.4 176 $70.00 - $79.90 77.54 3 77.54 1.2 3 $80.00 - $89.90 87.18 23 87.18 1.7 23 $90.00 - $99.90 90.04 21 90.04 1.8 21 $100.00 - $266.90 109.49 6 109.49 1.8 6 707 2.6 707 For the three months ended June 30, 2018 and 2017, the Company recognized $ 1.0 0.4 0.009 0.015 1.0 0.4 0.9 0.9 0.02 0.026 0.9 0.9 0.02 0.3 Reverse Stock Split The Company effected a 1-for-10 reverse stock split of its outstanding common stock on October 5, 2017. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $ 0.001

Related Party

Related Party	6 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Related Party In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director was then a member of the Board of Directors. During the three months ended June 30, 2018 and 2017, the Company incurred costs of approximately $ 0.07 0.1 0.26 0.26 0 0.1

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Fair Value Measurement Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. Warrant Liabilities On June 30, 2018, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 210,000 164,000 79.54 2.68 3.58 0.00 15,000 34,000 Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer. Six Months Ended June 30, 2018 2017 Warrant Liabilities Beginning balance as of January 1, $ 130 $ 20 Change in fair value of warrant liability 34 (369) Warrant modification expense - 803 Ending balance as of March 31, $ 164 $ 454 Six Months Ended June 30, 2018 2017 Contingent Consideration Beginning balance as of January 1, $ - $ 1,816 Payments of contingent consideration - (1,851) Change in fair value of contingent consideration - 35 Ending balance as of March 31, $ - $ - June 30, 2018 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 164 Total liabilities $ - $ - $ 164 December 31, 2017 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 130 Total liabilities $ - $ - $ 130

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes In accordance with ASC 740-270, Income Taxes – Interim Reporting 0.5 21 34 The United States enacted the Tax Cuts and Jobs Act (“Act”) on December 22, 2017, most provisions of which took effect in years beginning after December 31, 2017. The Act made substantial changes to U.S. taxation of corporations, including a reduction in the U.S. federal corporate income tax rate from 34% to 21% and changes to limitations on the deductibility of executive compensation. The effect on deferred tax assets and liabilities of a change in law or tax rates is recognized in income in the period that includes the enactment date. After the enactment of the Act, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. In our financial statements for the period ended December 31, 2017, we calculated an estimate of the impact of the Act related to the remeasurement of our net U.S. deferred tax asset due to the change in U.S. federal corporate income tax rate. The provisional amount recorded was deferred tax expense of $ 14.6 1.3

Description of Business and B19

Description of Business and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Recent Developments [Policy Text Block]	On May 7, 2018, the Company completed its previously announced Asset Sale Transaction (the “AST”) with Celularity, Inc. (“Celularity”), pursuant to which the Company sold substantially all of its assets to Celularity, including certain assets comprising its MIST, Biovance and Interfyl Product Lines (the “Purchased Assets”). As consideration for the Purchased Assets, Celularity paid $ 29.0 14.8 The transactions contemplated by the APA were approved by the affirmative vote of a majority of the voting power of issued and outstanding shares of the Company’s common stock on April 27, 2018. The Company’s operations sold under the APA have been reclassified to discontinued operations in the second quarter of 2018, when the shareholders of the Company approved the sale. The AST was completed on May 7, 2018.
Basis of Accounting, Policy [Policy Text Block]	The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of June 30, 2018 and results of operations and cash flows for the three and six months ended June 30, 2018 and 2017. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Annual Report”). The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.
Consolidation, Policy [Policy Text Block]	The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations In addition to the aforementioned AST with Celularity, effective August 31, 2017 the Company entered into an Asset Purchase Agreement (“the Argentum Purchase Agreement”) with Argentum Medical, LLC. (“Argentum”) whereby the Company agreed to sell to Argentum all of the Company’s rights, including (i) all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the TheraBond product line and (ii) the unsold inventory of TheraBond products and work in process previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Argentum Purchase Agreement. In consideration for the sale of the TheraBond product line and the unsold TheraBond inventory to Argentum by the Company, Argentum agreed to pay (i) $ 3.6 0.1 3.6 0.3 0.1 0.2 Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Revenue, net of returns, allowances and discounts $ 1,844 $ 4,905 $ 6,681 $ 9,261 Cost of revenues 504 1,337 1,791 2,575 Gross profit 1,340 3,568 4,890 6,686 Selling, general and administrative 5,140 6,088 11,485 13,031 Interest expense 64 596 612 1,169 Warrant modification expense - 33 - 803 Loss from discontinued operations, net of tax (3,864) (3,149) (7,207) (8,317) Note: The discontinued operations were sold on May 7, 2018. Non-cash amortization expense of $ 0.4 1.2 1.4 2.3 5.5 0.5 Proceeds from sale Total Consideration 29,000 Less: Net book value of assets sold to Celularity Inventory, net (1,578) Intangibles, net (20,557) Goodwill (1,659) Fixed Assets, net (904) Other current assets 15 Total net book value of assets (24,683) Add: Net book value of liabilities extinguished due to sale Milestone payment 1,000 Other liabilities 717 Total net book value of liabilities 1,717 Less: State tax expense (513) Net gain on sale of assets $ 5,521 June 30, December 31, 2018 2017 Accounts receivable, net $ 1,024 $ 3,161 Inventory, net - 1,458 Prepaid expenses and other current assets 200 443 Total current assets 1,224 5,062 Fixed assets, net - 1,041 Intangible assets, net - 22,069 Goodwill, net - 1,659 Total assets of discontinued operations 1,224 29,831 Accounts payable 2,169 957 Accrued expenses and other current liabilities 131 3,557 Senior secured term loan, net - 10,929 Total current liabilities $ 2,300 $ 15,443 Other long-term liabilities - 245 Total liabilities of discontinued operations $ 2,300 $ 15,688
Significant Accounting Policies and Estimates [Policy Text Block]	Significant Accounting Policies and Estimates The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Principles In June 2018, the FASB issued ASU 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”. The amendments in this update is to maintain or improve the usefulness of the information provided to the users of financial statements while reducing cost and complexity in financial reporting. The areas for simplification in this Update involve several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, to include share-based payment transactions for acquiring goods and services from nonemployees. Some of the areas for simplification apply only to nonpublic entities. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements. In February 2018, the FASB issued ASU 2018-02, “Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. The amendments in this Update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Consequently, the amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users. However, because the amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. The amendments in this Update also require certain disclosures about stranded tax effects. The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company does not expect that this guidance will have a material impact on its consolidated financial statements.

Description of Business and B20

Description of Business and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Disposal Groups, Including Discontinued Operations [Table Text Block]	Summarized operating results of discontinued operations for the three and six months ended June 30, 2018 and 2017 are presented in the following table (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Revenue, net of returns, allowances and discounts $ 1,844 $ 4,905 $ 6,681 $ 9,261 Cost of revenues 504 1,337 1,791 2,575 Gross profit 1,340 3,568 4,890 6,686 Selling, general and administrative 5,140 6,088 11,485 13,031 Interest expense 64 596 612 1,169 Warrant modification expense - 33 - 803 Loss from discontinued operations, net of tax (3,864) (3,149) (7,207) (8,317)
Schedule of Gain Loss on Disposal of Discontinued Operations [Table Text Block]	During the three and six months ended June 30, 2018, the Company recorded a net gain of approximately $ 5.5 0.5 Proceeds from sale Total Consideration 29,000 Less: Net book value of assets sold to Celularity Inventory, net (1,578) Intangibles, net (20,557) Goodwill (1,659) Fixed Assets, net (904) Other current assets 15 Total net book value of assets (24,683) Add: Net book value of liabilities extinguished due to sale Milestone payment 1,000 Other liabilities 717 Total net book value of liabilities 1,717 Less: State tax expense (513) Net gain on sale of assets $ 5,521
Schedule of Closed Block Assets and Liabilities [Table Text Block]	Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands): June 30, December 31, 2018 2017 Accounts receivable, net $ 1,024 $ 3,161 Inventory, net - 1,458 Prepaid expenses and other current assets 200 443 Total current assets 1,224 5,062 Fixed assets, net - 1,041 Intangible assets, net - 22,069 Goodwill, net - 1,659 Total assets of discontinued operations 1,224 29,831 Accounts payable 2,169 957 Accrued expenses and other current liabilities 131 3,557 Senior secured term loan, net - 10,929 Total current liabilities $ 2,300 $ 15,443 Other long-term liabilities - 245 Total liabilities of discontinued operations $ 2,300 $ 15,688

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: As of June 30, 2018 2017 Stock options 706,666 921,050 Warrants 400,307 517,167 Non-vested restricted stock 20,000 261,603 Total 1,126,973 1,699,820

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following (in thousands): June 30, December 31, 2018 2017 Raw materials $ 129 $ 98 Work in process 8 - Finished goods 2 - Less: Inventory reserve for excess and slow moving inventory - (5) Total $ 139 $ 93

Accrued Expenses and Other Cu23

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2018
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities consist of the following (in thousands): June 30, December 31, 2018 2017 Salaries, benefits and incentive compensation $ 71 $ 509 Professional fees 129 176 Other 49 27 Total accrued expenses and other current liabilities $ 249 $ 712

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2018
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Range of Weighted Outstanding Weighted Average Weighted Exercisable $2.00 - $4.00 $ 3.51 215 3.51 2.3 215 $4.10 - $9.90 8.53 28 8.53 6.3 28 $10.00 - $19.90 10.57 76 10.57 1.2 76 $20.00 - $29.90 23.80 1 23.80 0.1 1 $30.00 - $39.90 33.63 46 33.63 4.3 46 $40.00 - $49.90 46.34 69 46.34 1.7 69 $50.00 - $59.90 52.92 43 52.92 1.1 43 $60.00 - $69.90 66.09 176 66.09 3.4 176 $70.00 - $79.90 77.54 3 77.54 1.2 3 $80.00 - $89.90 87.18 23 87.18 1.7 23 $90.00 - $99.90 90.04 21 90.04 1.8 21 $100.00 - $266.90 109.49 6 109.49 1.8 6 707 2.6 707

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands): Six Months Ended June 30, 2018 2017 Warrant Liabilities Beginning balance as of January 1, $ 130 $ 20 Change in fair value of warrant liability 34 (369) Warrant modification expense - 803 Ending balance as of March 31, $ 164 $ 454 Six Months Ended June 30, 2018 2017 Contingent Consideration Beginning balance as of January 1, $ - $ 1,816 Payments of contingent consideration - (1,851) Change in fair value of contingent consideration - 35 Ending balance as of March 31, $ - $ -
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands): June 30, 2018 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 164 Total liabilities $ - $ - $ 164 December 31, 2017 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 130 Total liabilities $ - $ - $ 130

Description of Business and B26

Description of Business and Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue, net of returns, allowances and discounts	$ 1,844	$ 4,905	$ 6,681	$ 9,261
Cost of revenues	504	1,337	1,791	2,575
Gross profit	1,340	3,568	4,890	6,686
Selling, general and administrative	5,140	6,088	11,485	13,031
Interest expense	64	596	612	1,169
Warrant modification expense	0	33	0	803
Loss from discontinued operations, net of tax	$ (3,864)	$ (3,149)	$ (7,207)	$ (8,317)

Description of Business and B27

Description of Business and Basis of Presentation (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Proceeds from sale
Total Consideration			$ 29,000
Less: Net book value of assets sold to Celularity
Inventory, net	$ (1,578)		(1,578)
Intangibles, net	(20,557)		(20,557)
Goodwill	(1,659)		(1,659)
Fixed Assets, net	(904)		(904)
Other current assets	15		15
Total net book value of assets	(24,683)		(24,683)
Add: Net book value of liabilities extinguished due to sale
Milestone payment	1,000		1,000
Other liabilities	717		717
Total net book value of liabilities	1,717		1,717
Less: State tax expense	500		500
Net gain on sale of assets	$ 5,521	$ 0	$ 5,521	$ 0

Description of Business and B28

Description of Business and Basis of Presentation (Details 2) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net	$ 1,024	$ 3,161
Inventory, net	0	1,458
Prepaid expenses and other current assets	200	443
Total current assets	1,224	5,062
Fixed assets, net	0	1,041
Intangible assets, net	0	22,069
Goodwill, net	0	1,659
Total assets of discontinued operations	1,224	29,831
Accounts payable	2,169	957
Accrued expenses and other current liabilities	131	3,557
Senior secured term loan, net	0	10,929
Total current liabilities	2,300	15,443
Long term liabilities of discontinued operations	0	245
Total liabilities of discontinued operations	$ 2,300	$ 15,688

Description of Business and B29

Description of Business and Basis of Presentation (Details Textual) - USD ($) $ in Thousands	May 07, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Aug. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax		$ 5,521	$ 0	$ 5,521	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation		500		500
Disposal Group, Including Discontinued Operation, Maximum Amount To be Received for Unsold Inventory						$ 100
Disposal Group, Including Discontinued Operation, Consideration		3,600		3,600		$ 3,600
Disposal Group, Including Discontinued Operation, Escrow Deposit, Current		300		300
Payments for (Proceeds from) Deposit on Loan				100
Escrow Deposit		200		200
Celularity, Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 29,000
Perceptive Credit Holdings LP [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of Debt	$ 14,800			14,800
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax		5,500		5,500
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amortization of Intangible Assets		$ 400	$ 1,200	$ 1,400	$ 2,300

Going Concern (Details Textual)

Going Concern (Details Textual) - USD ($) $ in Thousands	May 07, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Net Income (Loss) Attributable to Parent, Total		$ (1,262)	$ (4,204)	$ (6,370)	$ (11,201)
Net Cash Provided by (Used in) Operating Activities				(7,458)	(7,984)
Cash and Cash Equivalents, at Carrying Value, Total		$ 11,021	$ 2,299	11,021	$ 2,299	$ 2,181	$ 5,580
Business Combination, Consideration Transferred				156,400
Proceeds from Lines of Credit				29,000
Perceptive Credit Holdings LP [Member]
Repayments of Debt	$ 14,800			$ 14,800

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,126,973	1,699,820
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	706,666	921,050
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	400,307	517,167
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	20,000	261,603

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Inventory [Line Items]
Raw materials	$ 129	$ 98
Work in process	8	0
Finished goods	2	0
Less: Inventory reserve for excess and slow moving inventory	0	(5)
Total	$ 139	$ 93

Accrued Expenses and Other Cu33

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$ 71	$ 509
Professional fees	129	176
Other	49	27
Total accrued expenses and other current liabilities	$ 249	$ 712

Debt (Details Textual)

Debt (Details Textual) - USD ($) $ in Thousands	May 07, 2018	Mar. 13, 2018	May 29, 2015
Perceptive Credit Holdings LP [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount	$ 14,800
Bridge Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 2,000
Debt Instrument, Interest Rate Terms		The BLN bore interest at a rate per annum equal to the sum of (i) the greater of (x) LIBOR and (y) 1%, plus (ii) an applicable margin of 9.75%.
Upfront Fee Payable		$ 250
Senior Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 15,500

Commitments and Contingencies (

Commitments and Contingencies (Details Textual)	Jul. 15, 2011
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage	9.75%

Stockholders' Equity (Details )

Stockholders' Equity (Details ) shares in Thousands	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Outstanding Number of Options (in shares) | shares	707
Options Exercisable, Exercisable Number of Options (in shares) | shares	707
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Exercisable, Weighted Average Remaining Life in Years (in years)	2 years 7 months 6 days
Exercise Price Range 2.00 - 4.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 2
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	4
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 3.51
Options Outstanding, Outstanding Number of Options (in shares) | shares	215
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 3.51
Options Exercisable, Weighted Average Remaining Life in Years (in years)	2 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	215
Exercise Price Range 4.10 - 9.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 4.10
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	9.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 8.53
Options Outstanding, Outstanding Number of Options (in shares) | shares	28
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 8.53
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	28
Exercise Price Range 10.00 - 19.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 10
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	19.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 10.57
Options Outstanding, Outstanding Number of Options (in shares) | shares	76
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 10.57
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 year 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	76
Exercise Price Range 20.00 - 29.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 20
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	29.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 23.80
Options Outstanding, Outstanding Number of Options (in shares) | shares	1
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 23.80
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	1
Exercise Price Range 30.00 - 39.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 30
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	39.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 33.63
Options Outstanding, Outstanding Number of Options (in shares) | shares	46
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 33.63
Options Exercisable, Weighted Average Remaining Life in Years (in years)	4 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	46
Exercise Price Range 40.00 - 49.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 40
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	49.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 46.34
Options Outstanding, Outstanding Number of Options (in shares) | shares	69
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 46.34
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 year 8 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	69
Exercise Price Range 50.00 - 59.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 50
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	59.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 52.92
Options Outstanding, Outstanding Number of Options (in shares) | shares	43
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 52.92
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 year 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	43
Exercise Price Range 60.00 - 69.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 60
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	69.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 66.09
Options Outstanding, Outstanding Number of Options (in shares) | shares	176
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 66.09
Options Exercisable, Weighted Average Remaining Life in Years (in years)	3 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	176
Exercise Price Range 70.00 - 79.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 70
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	79.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 77.54
Options Outstanding, Outstanding Number of Options (in shares) | shares	3
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 77.54
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 year 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	3
Exercise Price Range 80.00 - 89.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 80
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	89.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 87.18
Options Outstanding, Outstanding Number of Options (in shares) | shares	23
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 87.18
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 year 8 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	23
Exercise Price Range 90.00 - 99.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 90
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	99.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 90.04
Options Outstanding, Outstanding Number of Options (in shares) | shares	21
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 90.04
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 year 9 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	21
Exercise Price Range 100.00 - 266.90 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 100
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	266.90
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 109.49
Options Outstanding, Outstanding Number of Options (in shares) | shares	6
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 109.49
Options Exercisable, Weighted Average Remaining Life in Years (in years)	1 year 9 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	6

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 1,000	$ 400	$ 900	$ 900
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001		$ 0.001
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 9	15	$ 20	26
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	1,000	$ 400	900	$ 900
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 20		$ 20
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			3 months 18 days

Related Party (Details Textual)

Related Party (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 70	$ 100	$ 260	$ 260
Accounts Payable, Related Parties	$ 0		$ 0		$ 100

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 130	$ 20
Change in fair value of warrant liability	34	(369)
Warrant modification expense	0	803
Ending balance	164	454
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	0	1,816
Change in fair value of warrant liability	0	35
Payments of contingent consideration	0	(1,851)
Ending balance	$ 0	$ 0

Fair Value Measurement (Detai40

Fair Value Measurement (Details 1) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Liabilities:
Warrant liabilities	$ 164	$ 130	$ 454	$ 20
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	164	130
Total liabilities	$ 164	$ 130

Fair Value Measurement (Detai41

Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 164	$ 454	$ 164	$ 454	$ 130	$ 20
Fair Value Adjustment of Warrants	15	$ (250)	$ 34	$ (369)
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants To Purchase Common Stock			210,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 164		$ 164		$ 130
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate			79.54%
Fair Value Assumptions, Risk Free Interest Rate			2.68%
Fair Value Assumptions, Expected Term			3 years 6 months 29 days
Fair Value Assumptions, Expected Dividend Rate			0.00%

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Millions	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Income Taxes [Line Items]
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	$ 0.5	$ 0.5
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%		34.00%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount		$ 14.6
Unrecognised Deferred Tax Asstes Stock Compensation	$ 1.3	1.3
Discontinued Operation [Member]
Income Taxes [Line Items]
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation		$ 0.5	$ 0.5